Results 51 to 60 of about 2,682 (215)

Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

Journal of Primary Care & Community Health
Introduction: There remains an unmet need to reduce kidney and cardiovascular risk in patients with chronic kidney disease (CKD). This report is therefore intended to provide real-world clinical guidance to primary care providers on sodium-glucose co ...
Anjay Rastogi, Ashté Collins, Ellie Kelepouris, Wayne Kotzker, John P. Middleton, Minesh Rajpal, Prabir Roy-Chaudhury, Glenn M. Chertow   +7 more
doaj   +1 more source

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?

Cardiovascular Diabetology, 2020
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF).
Atsushi Tanaka, Koichi Node
doaj   +1 more source

SGLT2 Inhibitors in Cardio-Oncology

JACC: Advances
Background: According to available evidence, sodium-glucose cotransporter-2 inhibitors (SGLT2i) may confer cardioprotection in patients with cancer undergoing chemotherapy. Objectives: The objective of the study was to evaluate the impact of SGLT2i on all-cause mortality and heart failure (HF) outcomes in this population.
Spadafora L., Bernardi M., Sarto G., Simeone B., Rocco E., Carbone S., Dalla Vecchia L. A., Pedretti R. F. E., Valenti V., Di Mario R., Forte M., Frati G., Abbate A., Golino M., Versaci F., Peruzzi M., Sabouret P., Biondi Zoccai G., Sciarretta S.   +18 more
openaire   +2 more sources

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

SGLT2 Inhibitors for Nephrologists

EMJ Nephrology, 2022
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides. Sodium-glucose co-transporter-2 inhibitors are a relatively new class of oral antidiabetic drugs.
Mufti Baleegh-ur-Raheem Mahmood, Sidra Farishta   +1 more
openaire   +2 more sources

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk

Frontiers in Pharmacology, 2019
The effect of anti-diabetic medications on bone metabolism has received increasing attention, considering that type 2 diabetes mellitus is a common metabolic disorder with adverse effects on bone metabolism.
Yangli Ye, Chenhe Zhao, Jing Liang, Yinqiu Yang, Mingxiang Yu, Xinhua Qu   +5 more
doaj   +1 more source

Interventional Mitral Valve Edge‐to‐Edge Repair in Patients Above 85 Years of Age

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Mitral valve transcatheter‐edge‐to‐edge repair (M‐TEER) is routinely performed in patients with severe mitral regurgitation (MR) at high operative risk, frequently including elderly patients. Patients ≥ 85 years, however, are frequently excluded in clinical studies.
Florian Jürgens, Florian Schindhelm, Mohammed Abusharekh, Jürgen Kampf, Matthias Totzeck, Fadi Al‐Rashid, Peter Lüdike, Tienush Rassaf, Amir A. Mahabadi   +8 more
wiley   +1 more source

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz, Pimrapat Gebert, Jingwen Luo, Paraskevi Tassopoulou, Juliane Bolbrinker, Antonios Douros   +5 more
wiley   +1 more source

Renal effects of SGLT2 inhibitors

Current Opinion in Nephrology and Hypertension, 2020
SGLT2 inhibitors are a new class of antihyperglycemic drugs that protect kidneys and hearts of type 2 diabetic (T2DM) patients with preserved kidney function from failing. Here we discuss new insights on renal protection.Also in T2DM patients with CKD, SGLT2 inhibition causes an immediate functional reduction in glomerular filtration rate (GFR) and ...
Josselin, Nespoux, Volker, Vallon
openaire   +3 more sources